EGFR amplification induces sensitivity to anti EGFR therapy in pancreatic acinar cell carcinoma

Abstract : Pancreatic acinar cell carcinoma (PACC) is a rare cancer. When the tumor is metastatic, few therapeutic options are available. Precision medicine using next-generation sequencing is defined by the administration of drugs based on the tumor genetic mutations. The usage of precision medicine for finding new therapeutic options for rare cancers is an emerging field. We have reported here the case of a patient bearing a multitreated metastatic PACC. This patient underwent somatic and constitutional exome analyses. The analyses revealed in the liver metastasis an amplification of the EGFR gene. Accordingly, the patient was treated with off-label usage of panitumumab. We observed rapid response with necrosis of the liver metastasis, while no efficacy was observed in the primary tumor. An exome analysis of the primary tumor revealed amplification of HER2 and MET with EGFR amplification. Such amplifications are known as a resistance mechanism to antiEGFR therapy. Our results suggest that exome analysis may be helpful to highlight targets in rare cancers, such as PACC. EGFR amplification in this pathology should be determined and could be used as a biomarker to propose antiEGFR therapy.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01820136
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : jeudi 21 juin 2018 - 11:45:29
Dernière modification le : mercredi 5 septembre 2018 - 17:04:04

Lien texte intégral

Identifiants

Citation

Corentin Richard, Julie Niogret, Romain Boidot, François Ghiringhelli. EGFR amplification induces sensitivity to anti EGFR therapy in pancreatic acinar cell carcinoma. World Journal of Gastrointestinal Oncology, Baishideng Publishing Group, 2018, 10 (4), pp.103 - 107. ⟨10.4251/wjgo.v10.i4.103⟩. ⟨hal-01820136⟩

Partager

Métriques

Consultations de la notice

35